Win 49596-finasteride method of use and compositions
AssigneeSterling Winthrop Inc.
InventorsPaul E. Juniewicz, Bruce M. Berger
Life of this patent
Estimating the term…
Abstract
The method of use of a combination of the antiandrogen (5.alpha.,17.alpha.)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17 -ol (Win 49596) and the 5.alpha.-reductase inhibitor (5.alpha.,17.beta.)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carb oxamide (finasteride) for treating prostate disease in a male mammal and pharmaceutical compositions thereof are disclosed.
Claims6
The method of reducing the size or inhibiting the growth of the prostate in a male mammal which comprises administering to the mammal a combination of (5.alpha., 17.alpha.)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol17-ol and (5.alpha.,17.beta.)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carb oxamide in a weight ratio in the range from 100:1 to 1:1.
A pharmaceutical composition which comprises a combination of (5.alpha.,17.alpha.)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17 -ol and (5.alpha.,17.beta.)-N-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carb oxamide in a weight ratio in the range from 100:1 to 1:1 in a pharmaceutical vehicle.
Dependencies are inferred from the claim text.